Pharmaceutical News

RSS

Call for open challenges in nanomedicine

"Nanomedicine is certainly the most promising enabling technology to achieve breakthroughs in medical technologies. It will strongly contribute to driving the future of medicine. A first step to initiate the necessary actions will be done in October in Barcelona." says Bertrand Loubaton, Director at GE Healthcare and chairman of the European Technology Platform ETPN.

24 Aug 2011

FDA grants fast track designation for Pharmasset's PSI-938 to treat chronic HCV infection

Pharmasset, Inc. has received fast track designation from the U.S. Food and Drug Administration (FDA) for PSI-938 for the treatment of chronic hepatitis C virus (HCV) infection.

24 Aug 2011

$New invasive procedures may help patients with chronic refractory headache$

New invasive procedures may help patients with chronic refractory headache

Cluster headache has a substantial detrimental effect on quality of life. New invasive procedures, such as hypothalamic deep brain stimulation and bilateral occipital nerve stimulation, may help patients with chronic refractory headache.

24 Aug 2011

New Pressurized Olfactory Device shows direct CNS effect of morphine

A simple new approach to nasal drug administration may allow morphine and other strong pain medications to be targeted directly to the central nervous system (CNS), reports an experimental study in the September issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

24 Aug 2011

First international conference on developmental, translational and clinical pharmacogenomics

The first international conference hosted by the University of South Florida College of Pharmacy will focus on ways to improve health care by customizing drug prescribing and treatment based on an individual's genetic makeup.

24 Aug 2011

Health Canada accepts Sunovion Pharmaceuticals Canada's lurasidone NDS for review

Sunovion Pharmaceuticals Canada Inc., formerly Sepracor Pharmaceuticals, Inc., today announced that the New Drug Submission (NDS) for Lurasidone HCl, for the treatment of adult patients with schizophrenia has been accepted for review by Health Canada. The NDS was submitted to Health Canada in June 2011 and will receive a standard review.

24 Aug 2011

Research may help explain why live attenuated influenza vaccine elicits protection

New research from the Trudeau Institute may help to explain why live attenuated influenza vaccine (LAIV), commonly known as FluMist, elicits protection.

24 Aug 2011

Daily exercise can work as well as second antidepressant drug

Exercise can be as effective as a second medication for as many as half of depressed patients whose condition have not been cured by a single antidepressant medication.

24 Aug 2011

Simvastatin may reduce spinal cord damage from ischemia/reperfusion injury

The cholesterol-lowering drug simvastatin appears to reduce spinal cord injury caused by oxygen deprivation in experimental animals, according to a study in the September issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

24 Aug 2011

Only 20.6% of Medicaid-covered Ohio youths complete full six month antidepressant treatment

About half of Medicaid-covered children and adolescents in Ohio who are in treatment for depression complete their first three months of prescribed antidepressants, and only one-fifth complete the recommended minimum six-month course of drugs to treat depression, new research suggests.

24 Aug 2011

Trophos awarded US patent covering use of novel cardioprotective compound

Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos’ TRO40303 to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen after a heart attack (myocardial infarction - MI).

23 Aug 2011

Seattle genetics new blood cancer drug Adcetris comes with a hefty price tag

Seattle Genetics Inc's new blood cancer drug Adcetris is will come with a price tag of $100,000 for a course of treatment. The U.S. Food and Drug Administration on Friday gave its nod to Adcetris, the first drug specifically indicated for anaplastic large cell lymphoma (ALCL) and the first one approved for Hodgkin's lymphoma since 1977.

23 Aug 2011

Kerr, Family Health Network partner to reduce medication non-adherence

Family Health Network is pleased to announce its participation in a program in partnership with Kerr Health, a subsidiary of the renowned regional pharmacy chain, Kerr Drug. Kerr Health will deploy Family Health Network's Connected for Life(SM) platform to an initial group of patients who require frequent interaction with a pharmacist to assist them with medication therapy management.

23 Aug 2011

Prescription drug shortages forcing docs, pharmacists to scramble

Record shortages of prescription drugs in the United States are forcing pharmacists and doctors to scramble to find medications for their patients, suitable alternatives or to delay potentially lifesaving treatments.

23 Aug 2011

Radium-223 chloride granted FDA Fast Track designation for treatment of CRPC

Algeta ASA, a company focused on the development of novel targeted cancer therapeutics, today announced that radium-223 chloride has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of castration-resistant (hormone refractory) prostate cancer in patients with bone metastases.

23 Aug 2011

Research into TB medication may shorten treatment regimen

Research of the common tuberculosis (TB) drug pyrazinamide, which is used in combination with other medications to treat the disease in a six-month regimen, "has now revealed that the drug does kill the latent form of the microbe, which does not cause observable symptoms," VOA News reports.

23 Aug 2011

Santarus, Depomed enter new commercialization agreement for GLUMETZA

Santarus, Inc. and Depomed, Inc. today announced that they have entered into a new commercialization agreement for GLUMETZA (metformin hydrochloride extended release tablets) under which Santarus will assume broad commercial, manufacturing and regulatory responsibilities to replace a promotion agreement that the companies entered into in July 2008.

23 Aug 2011

CTI responds to EMA's Day 120 letter for pixantrone MAA

Cell Therapeutics, Inc. today announced that it has submitted its response to the Day 120 List of Outstanding Issues to the European Medicines Agency's Committee for Medicinal Products for Human Use in regards to CTI's Marketing Authorization Application for pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma.

23 Aug 2011

New report on the immunomodulators market outlook to 2016

TNF inhibitors indicated for the treatment of rheumatoid arthritis, psoriasis and inflammatory bowel disease formed the largest share of the market, according to a new report available on companiesandmarkets.com. The top three products: Remicade, Humira and Enbrel accounted for 40.1% of the market in 2010.

23 Aug 2011

NovaDel, Rechon enter license and distribution agreement for Zolpimist

NovaDel Pharma Inc., a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today announced its entry into an exclusive license and distribution agreement with Rechon Life Science AB to manufacture and commercialize Zolpimist® outside the United States and Canada. Zolpimist is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.

23 Aug 2011